S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)

Seelos Therapeutics (SEEL) Stock Price, News & Analysis

$1.39
-0.06 (-4.14%)
(As of 12/29/2023 ET)
Today's Range
$1.35
$1.51
50-Day Range
$1.25
$6.46
52-Week Range
$1.04
$49.80
Volume
420,253 shs
Average Volume
990,092 shs
Market Capitalization
$10.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.00

Seelos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
4,936.0% Upside
$70.00 Price Target
Short Interest
Bearish
9.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

528th out of 950 stocks

Pharmaceutical Preparations Industry

248th out of 442 stocks


SEEL stock logo

About Seelos Therapeutics Stock (NASDAQ:SEEL)

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

SEEL Stock Price History

SEEL Stock News Headlines

New Year's Sale: Get 12 Months of Stock Picks for $9.00
Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this.
Seelos Therapeutics Announces Closing of Public Offering
Claim Your $300 MarketBeat Account Credit
Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)
Why Is Seelos Therapeutics (SEEL) Stock Down 42% Today?
Seelos Therapeutics Announces Proposed Public Offering
Seelos to Implement 1-for-30 Reverse Stock Split
Why Seelos Therapeutics Shares Are Diving Today
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
Dole (DOLE) Q3 Earnings Top Estimates
See More Headlines
Receive SEEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/13/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SEEL
Employees
16
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$70.00
High Stock Price Target
$120.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+4,936.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-73,530,000.00
Pretax Margin
-3,295.87%
Return on Equity
-10,287.49%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($2.97) per share

Miscellaneous

Free Float
6,974,000
Market Cap
$10.24 million
Optionable
Not Optionable
Beta
1.82

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Raj Mehra J.D. (Age 63)
    Ph.D., Founder, Chairman, CEO & President
    Comp: $854.73k
  • Mr. Michael J. Golembiewski (Age 51)
    Chief Financial Officer
    Comp: $454.83k
  • Ms. Kimberly Farrand
    Senior Director of Clinical Development & Operations
  • Mr. Anthony Marciano
    Chief Communications Officer
  • Gopal Krishna Ph.D.
    Head of Manufacturing & Technical Operations
  • Tim Whitaker M.D.
    Chief Medical Officer
  • Ms. Karen Fusaro
    Senior VP & Head of Clinical Operations














SEEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Seelos Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SEEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SEEL, but not buy additional shares or sell existing shares.
View SEEL analyst ratings
or view top-rated stocks.

What is Seelos Therapeutics' stock price target for 2024?

3 analysts have issued 12 month price targets for Seelos Therapeutics' stock. Their SEEL share price targets range from $30.00 to $120.00. On average, they predict the company's stock price to reach $70.00 in the next twelve months. This suggests a possible upside of 4,936.0% from the stock's current price.
View analysts price targets for SEEL
or view top-rated stocks among Wall Street analysts.

How have SEEL shares performed in 2023?

Seelos Therapeutics' stock was trading at $20.37 at the beginning of 2023. Since then, SEEL shares have decreased by 93.2% and is now trading at $1.39.
View the best growth stocks for 2023 here
.

When is Seelos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our SEEL earnings forecast
.

How were Seelos Therapeutics' earnings last quarter?

Seelos Therapeutics, Inc. (NASDAQ:SEEL) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($8.41) earnings per share (EPS) for the quarter. The firm earned $0.41 million during the quarter.

What ETF holds Seelos Therapeutics' stock ?

AdvisorShares Psychedelics ETF holds 312,582 shares of SEEL stock, representing 5.70% of its portfolio.

When did Seelos Therapeutics' stock split?

Shares of Seelos Therapeutics reverse split on Tuesday, November 28th 2023. The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), OPKO Health (OPK).

How do I buy shares of Seelos Therapeutics?

Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SEEL) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -